Literature DB >> 7958496

Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM.

C Y Jeng1, W H Sheu, M M Fuh, Y D Chen, G M Reaven.   

Abstract

This study was initiated to reevaluate the changes in basal hepatic glucose production (HGP) rate that occur in patients with non-insulin-dependent diabetes mellitus (NIDDM). Measurements were made in 51 volunteers: 18 with normal glucose tolerance and 33 with newly diagnosed NIDDM of varying degrees of severity. To avoid the methodological problems associated with quantifying HGP over short time periods, using non-steady-state isotopic kinetics, radiolabeled glucose was infused for a 12-h period, from 10 P.M. to 10 A.M. with HGP quantified from 9 to 10 A.M.. The results showed that fasting plasma glucose (FPG) concentration and HGP were significantly correlated (r = 0.68, P < 0.001) in patients with NIDDM. However, when the 33 patients with NIDDM were divided into three groups of 11 each on the basis of FPG concentration, it became clear that the relationship between FPG and HGP was complex. Thus, values for HGP in patients with NIDDM and FPG < 180 mg/dl were not higher than in the normal population (1.67 +/- 0.07 vs. 1.69 +/- 0.04 mg.kg-1.min-1, NS). Significant increases (P < 0.01) in HGP above normal were seen in the 11 patients with NIDDM and FPG concentrations between 180 and 250 mg/dl (2.05 +/- 0.07 mg.kg-1.min-1), as well as in those with FPG > 250 mg/dl (2.18 +/- 0.13 mg.kg-1.min-1). Although those with the highest FPG concentrations tended to have the greatest values for HGP, the difference between the latter two groups of patients with NIDDM was not statistically significant. Finally, HGP rates in the 11 patients with FPG concentrations > 250 mg/dl were only 29% higher than values in the control population.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7958496     DOI: 10.2337/diab.43.12.1440

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  28 in total

Review 1.  Is hepatic glucose production increased in type 2 diabetes mellitus?

Authors:  Henning Beck-Nielsen; Ole Hother-Nielsen; Peter Staehr
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 2.  The role of the liver in type 2 diabetes.

Authors:  Peter Staehr; Ole Hother-Nielsen; Henning Beck-Nielsen
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

3.  Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour?

Authors:  J Radziuk; S Pye
Journal:  Diabetologia       Date:  2006-05-16       Impact factor: 10.122

4.  Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.

Authors:  Sung Kweon Cho; Choon Ok Kim; Eun Seok Park; Jae-Yong Chung
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

5.  Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs.

Authors:  K Rebrin; G M Steil; S D Mittelman; R N Bergman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

6.  Deletion of CaMKK2 from the liver lowers blood glucose and improves whole-body glucose tolerance in the mouse.

Authors:  Kristin A Anderson; Fumin Lin; Thomas J Ribar; Robert D Stevens; Michael J Muehlbauer; Christopher B Newgard; Anthony R Means
Journal:  Mol Endocrinol       Date:  2012-01-12

Review 7.  Mitochondrial dysfunction and type 2 diabetes.

Authors:  Rebecca Parish; Kitt Falk Petersen
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

8.  Decreased basal hepatic glucose uptake in impaired fasting glucose.

Authors:  Mariam Alatrach; Christina Agyin; John Adams; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  Diabetologia       Date:  2017-03-22       Impact factor: 10.122

Review 9.  Metformin: new understandings, new uses.

Authors:  Ripudaman S Hundal; Silvio E Inzucchi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes.

Authors:  D Tripathy; K F Eriksson; M Orho-Melander; J Fredriksson; G Ahlqvist; L Groop
Journal:  Diabetologia       Date:  2004-04-28       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.